TuHURA Biosciences
Market cap $92.1M 65.8M shares (10-Q, Nov 10, 2026) × $1.40 close Nov 17, 2026
Most recent annual filing: 2026-03-31
- IFx-2.0 filing2H 2026IFx-2.0 filing, 2H 2026, notable
- TBS-2025 Ph1 start2H 2026TBS-2025 Ph1 start, 2H 2026, routine
- TBS-2025 / DOR ADC corporate2H 2026TBS-2025 / DOR ADC corporate, 2H 2026, routine
- HURA corporate updateNov 2026HURA corporate update, Nov 2026, routine
- TBS-2025 readout1H 2027TBS-2025 readout, 1H 2027, notable
- IFx-2.0 readout1H 2027IFx-2.0 readout, 1H 2027, notable
- HURA corporate manufacturing updateApr 21, 2027HURA corporate manufacturing update, Apr 21, 2027, routine
- IFx-2.0 Ph3 topline2H 2027IFx-2.0 Ph3 topline, 2H 2027, major
- Parkview credit facility manufacturing updatelate 2027Parkview credit facility manufacturing update, late 2027, routine
- HURA corporate financingDec 10, 2027HURA corporate financing, Dec 10, 2027, routine
- IFx-2.0 topline~Jan–Jul 2028IFx-2.0 topline, ~Jan–Jul 2028, thesis-defining
- HURA corporate financing~Feb–Apr 2028HURA corporate financing, ~Feb–Apr 2028, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
TBS-2025
KVA12123Technology platforms
Immune Fx
Innate immune agonist platform using plasmid DNA or mRNA to express immunogenic gram-positive bacterial protein (Emm55) on tumor cell surfaces, triggering innate immune recognition and overcoming primary resistance to checkpoint inhibitors; delivered via intratumoral injection (pDNA) or intravenous/autologous whole-cell administration (mRNA); focus: solid tumors and immuno-oncology
Targets: TLR-2
Delta Opioid Receptor
Delta Opioid Receptor (DOR) technology used to develop first-in-class bi-specific, bi-functional antibody drug conjugates (ADCs) targeting Myeloid Derived Suppressor Cells to inhibit immune-suppressing effects in the tumor microenvironment; focus area: prevention of T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies in AML
Targets: DOR, VISTA, Delta Opioid Receptor, MDSC
DOR
Delta Opioid Receptor (DOR) technology platform developing small molecule bi-specific/bi-functional ADCs targeting DOR on tumor-associated MDSCs to modulate immunosuppression in bone marrow and tumor microenvironment; focus area: oncology, acquired resistance to checkpoint inhibitors
Targets: DOR
Delta Opioid Receptor ADC
DOR antagonist-based bi-specific, bi-functional antibody drug conjugate technology targeting Delta Opioid Receptor (DOR) on Myeloid-Derived Suppressor Cells (MDSCs) to inhibit immunosuppression in the tumor microenvironment; also applicable to adoptive cellular immunotherapies (CAR-T, Treg, TIL); preclinical focus on blood-related cancers including AML and MDS
Targets: DOR, MDSCs
Discontinued (1)
- IFx-3.0 — undisclosed · resources reallocated to TBS-2025; development paused pending IFx-2.0 Phase 3 results
Capital (as filed)
- Cash
- $1.9M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$5.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $1.9M cash, runway into 2028 per the update of Nov 13, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (3)
- 2026-11-14 UPDATE: TuHURA Biosciences (HURA) - The Meter Runs Faster 🔒 Paid
- 2026-10-27 UPDATE: TuHURA Biosciences (HURA) - Three for Three, Riding Shotgun 🔒 Paid
- 2026-10-13 TuHURA Biosciences (HURA) - Scientific Deep Dive for IFx-2.0 (IFx-Hu2.0) and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (3 calls)
Every verdict Biotech Distilled has published on TuHURA Biosciences, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-10-13 Avoid TuHURA Biosciences (HURA) - Scientific Deep Dive for IFx-2.0 (IFx-Hu2.0) and Pipeline Products IFx-2.0 showed only one PR in 21 patients on protocol, the 66% headline is a post-hoc rechallenge count reported five ways, the Phase 3 needs an ORR gain roughly twice the best add-on identified, and the related-party revolver runs out around the readout.
- 2026-10-27 Avoid UPDATE: TuHURA Biosciences (HURA) - Three for Three, Riding Shotgun 3/3 PRs are consistent with Keytruda alone (~12-18% probability with no IFx-2.0 effect), there is no control arm, and none of the four WATCH LIST triggers were met.
- 2026-11-14 Avoid UPDATE: TuHURA Biosciences (HURA) - The Meter Runs Faster The draw pace has accelerated such that the Parkview facility likely runs out before the 2028 binary readout, the runway language was cut from 'end of 2028' to 'into 2028', enrollment remains undisclosed, and the $1.95 warrant lever is now out of the money.
- Avoid call · opened Oct 13, 2026 at $1.81 · -22.7% vs XBI -1.0% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (34)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Oct 13, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 13, 2026ReleaseTuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update→ BD updateSummary on the 8-K
- Nov 13, 20268-KCurrent report: results of operations · EX-99.1→ BD updateThe Q3 10-Q lands with no Phase 3 enrollment count, $4.95M in new Parkview draws since quarter-end that accelerate the facility burn rate, and a runway statement that quietly dropped "end of" before "2028" — the bear case tightens on every axis I flagged.
- Nov 13, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 6, 20268-KCurrent report: debt / obligation
- Nov 4, 2026ReleaseTuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
- Oct 26, 2026ReleaseTuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Ca→ BD updateTuHURA dropped first data from its interventional-radiology IFx-2.0 study today: 3 of 3 front-line MCC patients hit confirmed partial responses (RECIST 1.1) at 6 months when combined with pembrolizumab — the first time the combination has been tested in the first-line setting and a direct preview of the Phase 3 design, if not a proof of it.BD extracted 1 program update from this document → HURA pipeline
- Oct 16, 20268-KCurrent report: debt / obligation
- Oct 13, 2026ReleaseTuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025
- Sep 24, 20268-KCurrent report: debt / obligation
- Sep 17, 20268-K/ACurrent report (amended): officer / director change
- Sep 17, 20268-KCurrent report: debt / obligation
- Sep 16, 20268-KCurrent report: officer / director change
- Sep 4, 20268-KCurrent report: debt / obligation
- Aug 28, 2026SCHEDULE 13D/A13D amendment
- Aug 21, 20268-KCurrent report: debt / obligation
- Aug 19, 20268-KCurrent report: unregistered sale of equity, shareholder vote
- Aug 14, 20268-KCurrent report: results of operations · EX-99.1
- Aug 14, 202610-QQuarterly report
- Aug 13, 20268-KCurrent report: debt / obligation
- Jul 29, 20268-KCurrent report: debt / obligation
- Jul 9, 2026DEFA14AProxy soliciting material
- Jul 9, 2026DEF 14AProxy statement
- Jul 7, 20268-KCurrent report: debt / obligation
- Jun 17, 20268-KCurrent report: shareholder nominations
- May 29, 20268-KCurrent report: debt / obligation
- May 15, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- May 15, 202610-QQuarterly report
- Apr 30, 20268-K/ACurrent report (amended): other events · EX-99.1
- Apr 30, 202610-K/AAnnual report (amended)
- Apr 22, 20268-KCurrent report: material agreement, debt / obligation, unregistered sale of equity · EX-99.1
- Apr 8, 20268-KCurrent report: officer / director change, other events · EX-99.1
- Apr 8, 2026424B5Prospectus supplement (offering)
- Apr 1, 20268-KCurrent report: results of operations · EX-99.1
- Mar 31, 202610-KAnnual report
2 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Jul 9, 2026ARSAnnual report to shareholders
- Jun 26, 2026PRE 14APRE 14A